<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Rizopoulos, D.</title>
    <link>http://repub.eur.nl/res/aut/49646/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Autograft and pulmonary allograft performance in the second post-operative decade after the Ross procedure: insights from the Rotterdam Prospective Cohort Study (Article)</title>
      <link>http://repub.eur.nl/res/pub/37728/</link>
      <pubDate>2012-09-01T00:00:00Z</pubDate>
      <description>The objective of the present study was to report our ongoing prospective cohort of autograft recipients with up to 21 years of follow-up. All consecutive patients (n = 161), operated between 1988 and 2010, were analysed. Mixed-effects models were used to assess changes in echocardiographic measurements (n = 1023) over time in both the autograft and the pulmonary allograft. The mean patient age was 20.9 years (range 0.05-52.7)-66.5% were male. Early mortality was 2.5% (n = 4), and eight additional patients died during a mean follow-up of 11.6 ± 5.7 years (range 0-21.5). Patient survival was 90% [95% confidence interval (CI), 78-95] up to 18 years. During the follow-up, 57 patients required a re-intervention related to the Ross operation. Freedom from autograft reoperation and allograft re-intervention was 51% (95% CI 38-63) and 82% (95% CI 71-89) after 18 years, respectively. No major changes were observed over time in autograft gradient, and allograft gradient and regurgitation. An initial increase of sinotubular junction and aortic anulus diameter was observed in the first 5 years after surgery. The only factor associated with an increased autograft reoperation rate was pre-operative pure aortic regurgitation (AR) (hazard ratio 1.88; 95% CI 1.04-3.39; P= 0.037). We observed good late survival in patients undergoing autograft procedure without reinforcement techniques. However, over half of the autografts failed prior to the end of the second decade. The reoperation rate and the results of echocardiographic measurements over time underline the importance of careful monitoring especially in the second decade after the initial autograft operation and in particular in patients with pre-operative AR.</description>
    </item> <item>
      <title>Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time-to-Event Data (Article)</title>
      <link>http://repub.eur.nl/res/pub/33304/</link>
      <pubDate>2011-09-01T00:00:00Z</pubDate>
      <description>In longitudinal studies it is often of interest to investigate how a marker that is repeatedly measured in time is associated with a time to an event of interest. This type of research question has given rise to a rapidly developing field of biostatistics research that deals with the joint modeling of longitudinal and time-to-event data. In this article, we consider this modeling framework and focus particularly on the assessment of the predictive ability of the longitudinal marker for the time-to-event outcome. In particular, we start by presenting how survival probabilities can be estimated for future subjects based on their available longitudinal measurements and a fitted joint model. Following we derive accuracy measures under the joint modeling framework and assess how well the marker is capable of discriminating between subjects who experience the event within a medically meaningful time frame from subjects who do not. We illustrate our proposals on a real data set on human immunodeficiency virus infected patients for which we are interested in predicting the time-to-death using their longitudinal CD4 cell count measurements. </description>
    </item> <item>
      <title>Recommendations to improve the Positive and Negative Syndrome Scale (PANSS) based on item response theory (Article)</title>
      <link>http://repub.eur.nl/res/pub/33639/</link>
      <pubDate>2011-08-15T00:00:00Z</pubDate>
      <description>The adequacy of the Positive and Negative Syndrome Scale (PANSS) items in measuring symptom severity in schizophrenia was examined using Item Response Theory (IRT). Baseline PANSS assessments were analyzed from two multi-center clinical trials of antipsychotic medication in chronic schizophrenia (n = 1872). Generally, the results showed that the PANSS (a) item ratings discriminated symptom severity best for the negative symptoms; (b) has an excess of "Severe" and "Extremely severe" rating options; and (c) assessments are more reliable at medium than very low or high levels of symptom severity. Analysis also showed that the detection of statistically and non-statistically significant differences in treatment were highly similar for the original and IRT-modified PANSS. In clinical trials of chronic schizophrenia, the PANSS appears to require the following modifications: fewer rating options, adjustment of 'Lack of judgment and insight', and improved severe symptom assessment. </description>
    </item> <item>
      <title>A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event (Article)</title>
      <link>http://repub.eur.nl/res/pub/33774/</link>
      <pubDate>2011-05-30T00:00:00Z</pubDate>
      <description>Motivated by a real data example on renal graft failure, we propose a new semiparametric multivariate joint model that relates multiple longitudinal outcomes to a time-to-event. To allow for greater flexibility, key components of the model are modelled nonparametrically. In particular, for the subject-specific longitudinal evolutions we use a spline-based approach, the baseline risk function is assumed piecewise constant, and the distribution of the latent terms is modelled using a Dirichlet Process prior formulation. Additionally, we discuss the choice of a suitable parameterization, from a practitioner's point of view, to relate the longitudinal process to the survival outcome. Specifically, we present three main families of parameterizations, discuss their features, and present tools to choose between them. </description>
    </item>
  </channel>
</rss>